Related Experiment Video
Updated: Jun 11, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
[Thalidomide in oncological and hematological diseases]
Sanna-Maria Kivivuori1, Pekka Anttila
1HYKS, lasten veri- ja syöpätautien sekä kantasolusiirtoyksikkö, Lasten ja nuorten sairaala, PL 281, 0029 HUS.
Abstract:
Thalidomide is a drug with bad reputation from the 1960's as it appeared to be teratogenic by causing foetal anomalies. However, in the beginning of 1990s it was shown very antiangiogenic. Its immunological effects were known already from earlier studies. Nowadays its use is accepted in myeloma therapy. It is also used in many study protocols, e.g. in pediatric patients with brainstem tumors. Thalidomide should be used very cautiously for fertile patients because of its teratogenity. Other adverse effects are tiredness, obstipation, thrombosis, and polyneuropathy.
Related Concept Videos
Teratogenicity
Drugs that Destabilize Microtubules
Therapeutic Drug Monitoring: Affecting Factors
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
